H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 59 Citations 11,495 123 World Ranking 1811 National Ranking 64

Overview

What is he best known for?

The fields of study he is best known for:

  • Immune system
  • Gene
  • Cancer

Ferry Ossendorp focuses on Antigen presentation, Cytotoxic T cell, Immunology, Antigen and MHC class I. His Antigen presentation research integrates issues from Epitope, Molecular biology, CTL* and Cell biology. His study in Cytotoxic T cell is interdisciplinary in nature, drawing from both Dendritic cell, CD8, Major histocompatibility complex and T helper cell.

His study in Immunology focuses on T cell, Immune system and Vaccination. His Vaccination research is multidisciplinary, incorporating elements of Cancer and Disease. Ferry Ossendorp works mostly in the field of Antigen, limiting it down to concerns involving Internalization and, occasionally, In vitro.

His most cited work include:

  • Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors (547 citations)
  • CD4 T cells and their role in antitumor immune responses. (474 citations)
  • Decreased tumor surveillance in perforin-deficient mice. (428 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Antigen, Immunology, Cytotoxic T cell, Immune system and T cell. He has researched Antigen in several fields, including Molecular biology, Receptor and Cell biology. His study connects Ex vivo and Immunology.

Ferry Ossendorp has researched Cytotoxic T cell in several fields, including Epitope and Major histocompatibility complex. He interconnects Cancer, Cancer research, Adjuvant and In vivo in the investigation of issues within Immune system. Ferry Ossendorp works mostly in the field of Antigen presentation, limiting it down to topics relating to MHC class I and, in certain cases, MHC class II.

He most often published in these fields:

  • Antigen (36.90%)
  • Immunology (35.83%)
  • Cytotoxic T cell (30.48%)

What were the highlights of his more recent work (between 2018-2021)?

  • Cancer research (21.39%)
  • Immune system (28.88%)
  • Immunotherapy (17.65%)

In recent papers he was focusing on the following fields of study:

Ferry Ossendorp mainly investigates Cancer research, Immune system, Immunotherapy, T cell and Tumor microenvironment. His work deals with themes such as PD-L1, Monoclonal antibody and Cancer immunotherapy, which intersect with Cancer research. His studies deal with areas such as Cancer and Antigen as well as Immune system.

His T cell research is multidisciplinary, incorporating elements of Ex vivo, CD8, NFAT, Receptor and Epitope. His research investigates the connection with Epitope and areas like Peptide which intersect with concerns in Antigen presentation. His study in Immune checkpoint is interdisciplinary in nature, drawing from both Cytotoxic T cell, MHC class I and Cytokine.

Between 2018 and 2021, his most popular works were:

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. (66 citations)
  • Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models (34 citations)
  • PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors. (22 citations)

In his most recent research, the most cited papers focused on:

  • Immune system
  • Gene
  • Cancer

Ferry Ossendorp mainly focuses on Cancer research, Tumor microenvironment, Immunotherapy, Immune system and T cell. His Cancer research research is multidisciplinary, incorporating perspectives in PD-L1, Antitumor immunity and Checkpoint Blockade Immunotherapy. The Tumor microenvironment study combines topics in areas such as Chemotherapy, Doxorubicin, Chemoimmunotherapy, Monoclonal antibody and In vivo.

He has included themes like Cancer and Clinical evidence in his Immune system study. The concepts of his T cell study are interwoven with issues in Ex vivo, CD8, NFAT, Cancer immunotherapy and Genetically modified mouse. His Cancer immunotherapy research includes elements of Epitope, Ovalbumin, Antigen and Vaccination.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors

Ferry Ossendorp;Erica Mengedé;Marcel Camps;Rian Filius.
Journal of Experimental Medicine (1998)

700 Citations

Decreased tumor surveillance in perforin-deficient mice.

M. F. Van Den Broek;D. Kagi;F. Ossendorp;R. Toes.
Journal of Experimental Medicine (1996)

658 Citations

CD4 T cells and their role in antitumor immune responses.

René E.M. Toes;Ferry Ossendorp;Rienk Offringa;Cornelis J.M. Melief.
Journal of Experimental Medicine (1999)

612 Citations

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation.

Peter Michael Kloetzel;Ferry Ossendorp.
Current Opinion in Immunology (2004)

483 Citations

Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Sjoerd H. van der Burg;Ramon Arens;Ferry Ossendorp;Thorbald van Hall.
Nature Reviews Cancer (2016)

462 Citations

Therapeutic cancer vaccines

Cornelis J.M. Melief;Thorbald van Hall;Ramon Arens;Ferry Ossendorp.
Journal of Clinical Investigation (2015)

442 Citations

CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope

Ania Skowera;Richard J. Ellis;Ruben Varela-Calviño;Sefina Arif.
Journal of Clinical Investigation (2008)

360 Citations

Efficient Identification of Novel HLA-A * 0201-presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen PRAME by Proteasome-mediated Digestion Analysis

Jan H. Kessler;Nico J. Beekman;Sandra A. Bres-Vloemans;Pauline Verdijk.
Journal of Experimental Medicine (2001)

358 Citations

Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells

Monique Kleijmeer;Georg Ramm;Danita Schuurhuis;Janice Griffith.
Journal of Cell Biology (2001)

329 Citations

Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes

Gabrielle G. M. Pinkse;Odette H. M. Tysma;Cees A. M. Bergen;Michel G. D. Kester.
Proceedings of the National Academy of Sciences of the United States of America (2005)

320 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ferry Ossendorp

Cornelis J. M. Melief

Cornelis J. M. Melief

Leiden University Medical Center

Publications: 91

Sjoerd H. van der Burg

Sjoerd H. van der Burg

Leiden University Medical Center

Publications: 81

Bart O. Roep

Bart O. Roep

Leiden University Medical Center

Publications: 79

Mark Peakman

Mark Peakman

King's College London

Publications: 61

Mark J. Smyth

Mark J. Smyth

QIMR Berghofer Medical Research Institute

Publications: 60

Rienk Offringa

Rienk Offringa

Leiden University Medical Center

Publications: 57

Peter van Endert

Peter van Endert

Inserm : Institut national de la santé et de la recherche médicale

Publications: 51

Jacques Neefjes

Jacques Neefjes

Leiden University Medical Center

Publications: 49

Jan W. Drijfhout

Jan W. Drijfhout

Leiden University Medical Center

Publications: 39

Joseph A. Trapani

Joseph A. Trapani

Peter MacCallum Cancer Centre

Publications: 38

Stefan Stevanovic

Stefan Stevanovic

University of Tübingen

Publications: 38

Herman S. Overkleeft

Herman S. Overkleeft

Leiden University

Publications: 38

Ramon Arens

Ramon Arens

Leiden University Medical Center

Publications: 32

Carl G. Figdor

Carl G. Figdor

Radboud University Nijmegen

Publications: 32

David Price

David Price

University of Aberdeen

Publications: 31

Ulf Dittmer

Ulf Dittmer

University of Duisburg-Essen

Publications: 30

Something went wrong. Please try again later.